Sydney Children's Hospital, High Street, Randwick, NSW 2031, Australia.
Sydney Children's Hospital, High Street, Randwick, NSW 2031, Australia.
J Cyst Fibros. 2013 Mar;12(2):177-82. doi: 10.1016/j.jcf.2012.08.007. Epub 2012 Sep 19.
To determine the safety and efficacy of stoss therapy on vitamin D levels over a 12 month period in children with cystic fibrosis and vitamin D deficiency (<75 nmol/L).
Retrospective chart review of 142 paediatric CF patients from 2007 till 2011.
Thirty eight children received stoss therapy and 37 children with vitamin D deficiency were not treated and served as a control group. The stoss treated group had a significant and sustained increase in 25-hydroxyvitamin D levels measured at 1, 3, 6 and 12 months post treatment compared to controls (94.82 ± 41.0 nmol/L, p=0.001; 81.54 ± 24.6 nmol/L, p=0.001; 92.18 ± 36.5 nmol/L, p=0.008 and 64.6 ± 20.0 nmol/L, p=0.006 respectively). At 12 months post intervention, the mean difference in vitamin D levels from baseline between the stoss treated group and controls was significant at 15 nmol/L compared to 5 nmol/L (p=0.038).
Stoss therapy effectively achieves and maintains levels of 25-hydroxyvitamin D greater than 75 nmol/L over 12 months.
在 12 个月的时间内，确定冲击疗法对囊性纤维化合并维生素 D 缺乏症（<75nmol/L）患儿维生素 D 水平的安全性和疗效。
回顾性分析 2007 年至 2011 年间 142 例儿科 CF 患者的图表。
38 名儿童接受了冲击治疗，37 名维生素 D 缺乏症患儿未接受治疗作为对照组。与对照组相比，冲击治疗组在治疗后 1、3、6 和 12 个月时 25-羟维生素 D 水平显著持续升高（94.82±41.0nmol/L，p=0.001；81.54±24.6nmol/L，p=0.001；92.18±36.5nmol/L，p=0.008 和 64.6±20.0nmol/L，p=0.006）。干预后 12 个月，冲击治疗组与对照组相比，维生素 D 水平从基线的平均差异为 15nmol/L，具有统计学意义，而对照组为 5nmol/L（p=0.038）。
冲击疗法可有效达到并维持 12 个月内 25-羟维生素 D 水平大于 75nmol/L。
